Grossman Adam S's Form 4 filing
Adma Biologics, Inc.ADMA · filed Nov 22, 2024
- Accession no.
- 0001140361-24-047701
- Filed
- Nov 22, 2024
- Trade date
- Nov 22, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.03M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Grossman Adam SCIK 0001542517 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 22, 2024 | Common Stock | SSaleDisposed | −48,967 | $21.10F2 | −$1,033,203.7 | 1,989,007 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.13. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.